A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms (Q43832862)

27 November 2017

title

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms (English)

1 reference

27 November 2017

0 references

0 references

Malcolm Peet

1

1 reference

27 November 2017

David F Horrobin

series ordinal

2

1 reference

27 November 2017

E-E Multicentre Study Group

series ordinal

3

1 reference

27 November 2017

publication date

1 January 2002

1 reference

Journal of Psychiatric Research

27 November 2017

published in

1 reference

27 November 2017

volume

36

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

7-18

1 reference

A rating scale for drug-induced akathisia

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Placebo-controlled trial of glycine added to clozapine in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Purification and characterisation of phospholipase A2 from human epidermis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Membrane fatty acids, niacin flushing and clinical parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

D-cycloserine added to clozapine for patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Fish consumption and major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Schizophrenia as a prostaglandin deficiency disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: a common link between risk factors and coronary and peripheral vascular disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

The membrane hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

The positive and negative syndrome scale (PANSS) for schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Single measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake in middle-aged Japanese men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Omega 3 fatty acids and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Risperidone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Schizophrenic symptoms and dietary intake of n-3 fatty acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

A New Depression Scale Designed to be Sensitive to Change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Sustained Remission of Positive and Negative Symptoms of Schizophrenia Following Treatment With Eicosapentaenoic Acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Laterality changes accompanying symptom remission in schizophrenia following treatment with eicosapentaenoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Serotonin, a potent modulator of arachidonic acid turnover, interaction with glutamatergic receptor in brain cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Niacin skin flush in schizophrenia: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2801%2900048-6

10.1016/S0022-3956(01)00048-6

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference